Merck Raises EPS Outlook After Q2 Earnings

Health and Healthcare

Published: July 29, 2016 8:20 am

Last Updated: January 13, 2020 5:08 am

Drug giant Merck & Co. Inc. (NYSE: MRK) reported second-quarter 2016 results before markets opened Friday. The company reported quarterly adjusted diluted earnings per share (EPS) of $0.93 and revenues of $9.84 billion. In the same period a year ago, Merck reported EPS of $0.86 on revenues of $9.79 billion. Second-quarter results also compare to the Thomson Reuters consensus estimates for EPS of $0.91 and $9.78 billion in revenues.

Pharmaceutical sales rose 2% year over year, irrespective of currency exchange effects. Net income on a GAAP basis totaled $1.21 billion, while non-GAAP net income totaled $687 million. Non-GAAP net income excludes the impacts of $1.12 billion in expenses related to acquisitions and divestitures, $18 million in marketing and administrative expenses, and $207 million in R&D costs.

In its financial outlook statement, Merck raised the lower end of its full-year adjusted EPS estimate from $3.60 to $3.67. The top end of the range rose from $3.75 to $3.77. Revenue guidance remained at $39.1 billion to $40.1 billion.

Consensus estimates for the third quarter call for EPS of $0.98 and revenues of $10.07 billion. For the full year, analysts are looking for EPS of $3.72 and revenues of $39.49 billion.

Chairman and CEO Kenneth C. Frazier said:

Our results this quarter reflect our strategic focus on key launches, including KEYTRUDA and ZEPATIER, as well as our priority inline programs. We remain committed to advancing our pipeline, delivering a balanced and differentiated portfolio, and achieving long-term, sustainable growth.

Since the beginning of the year, Merck stock trades up about 10.6%, well above the Dow Jones Industrial Average gain of 5.9%. Over the past 12 months, however, Merck stock trades down about 0.2%, compared with a Dow gain of 4%.

Shares of Merck’s stock traded up nearly 1.5% in Friday’s premarket, at $59.30 in a 52-week range of $45.69 to $60.07. Thomson Reuters had a 12-month price target of $61.90 before the report.

Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.